Table 1.
Demographics and Baseline Neuropsychological Assessments.
| Demographics Assessments | Mean (SD) By: Drug Use and Diagnosis | P Value | |
|---|---|---|---|
| No Psychosis AE or Antipsychotic Use (n = 342) | Psychosis AE and/or Antipsychotic Use (n = 47) | ||
| Age, years | 75.08 (7.31) | 74.29 (6.97) | .488 |
| Sex: male/female, % | 60/40 | 62/38 | |
| Diagnosis: MCI/AD, % | 71/29 | 51/49 | |
| Education, years | 15.52 (3.01) | 15.49 (3.44) | .943 |
| APOE4a | |||
| No E4 | 140 (41%) | 17 (36%) | |
| 1 E4 | 150 (44%) | 18 (38%) | |
| 2 E4 | 52 (15%) | 12 (26%) | |
| MMSE | 26.07 (2.46) | 24.96 (2.14) | .003 |
| ADAS-cog | 13.37 (5.89) | 15.13 (5.33) | .053 |
| NPI, mean | 1.93 (2.50) | 3.68 (3.85) | < .001 |
Abbreviations: AE, adverse event; AD, Alzheimer’s disease; ADAS-cog, AD Assessment Scale-cognitive subscale; APOE4, apolipoprotein E, MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination score; NPI, Neuropsychiatric Inventory; SD, standard deviation.
a Between group difference nonsignificant (chi-square.20).